Article
Increased vascular-endothelial growth factor (VEGF) tumor expression and response to epidermal growth factor receptor (EGF-R) inhibitor erlotinib in non-small cell lung cancer (NSCLC).
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Mar 2008
Brueckl Wolfgang M, Schoeberl Anja, Wirtz Ralph M, Murray Samuel, Hahn Eckhart G, Wiest Gunther H
Abstract excerpt
A 37-year-old female never smoker with metastatic large cell carcinoma of the lung had a partial response to a second line palliative therapy with the EGF-R tyrosine kinase inhibitor erlotinib after platinum based first line therapy failed. Molecular analysis of the primary and a liver metastasis did neither find any EGF-R mutation nor an EGF-R amplification. However, both the primary and the metastasis showed an...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.